Women's healthcare major
) will showcase the benefits of its leading-edge 3D mammography
systems at the 23rd Annual National Interdisciplinary Breast
Cancer Conference in Las Vegas hosted by the National Consortium
of Breast Cancer (NCBC).
The company will resort to a mobile coach tour at the conference
to expand its reach. The innovative initiative dubbed '3D
Technology: A More Accurate Mammogram' should publicize the
clinical benefits of its 3D mammography systems to the medical
community and target population. According to the company, a
mobile configuration will increase the scope of its critical
screening tool for women who otherwise do not have the access to
technically advanced systems for breast imaging.
Results from clinical studies demonstrate the efficacy of
Hologic's well-regarded technology as its 3D mammography in
conjunction with the routine 2D imaging improves detection of
cancer. It also decreases the need for callbacks as shown by the
findings from the study titled
Comparison of Digital Mammography Alone and Digital
Mammography Plus Tomosynthesis in a Population-based Screening
. The increase in detection rate and decrease in the need for
callbacks is crucial for women with restricted access to annual
Although mortality rate from breast cancer declined 31% since
1990 on the heels of higher detection rates with mammographic
screening, more than 40% American women still undergo only
regular screening. This is mainly due to lack of easy access for
these women. Hologic's mobile mammography addresses this issue by
enabling point-of-care mammographic screening for women.
Apart from its 3D mammography systems, the company will also
display its Advanced Body Composition Assessment package for the
osteoporosis assessment system, new tomosynthesis biopsy option
to be used on the Affirm biopsy guidance system. Hologic also
plans to showcase its CE marked synthesized 2D (C-View) images.
Offering a wide range of products, Hologic is arguably an
industry leader in the field of women's health. Going forward, we
are optimistic about increasing uptake of the company's
technically advanced solutions.
The stock carries a Zacks Rank #3 (Hold). Although we remain on
the sidelines for Hologic, we believe that other medical stocks
) are likely to do well. These stocks carry a Zacks Rank #2 (Buy)
ABAXIS INC (ABAX): Free Stock Analysis Report
CONCEPTUS INC (CPTS): Free Stock Analysis
CYBERONICS INC (CYBX): Free Stock Analysis
HOLOGIC INC (HOLX): Free Stock Analysis
To read this article on Zacks.com click here.